Related Experiment Video
Updated: Aug 9, 2026
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Cell encapsulation technology as a therapeutic strategy for CNS malignancies
T Visted1, R Bjerkvig, P O Enger
1Department of Anatomy and Cell Biology, University of Bergen, Norway.
Abstract:
Gene therapy using viral vectors has to date failed to reveal its definitive clinical usefulness. Cell encapsulation technology represents an alternative, nonviral approach for the delivery of biologically active compounds to tumors. This strategy involves the use of genetically engineered producer cells that secrete a protein with therapeutic potential. The cells are encapsulated in an immunoisolating material that makes them suitable for transplantation. The capsules, or bioreactors, permit the release of recombinant proteins that may assert their effects in the tumor microenvironment. During the last decades, there has been significant progress in the development of encapsulation technologies that comprise devices for both macro- and microencapsulation. The polysaccharide alginate is the most commonly used material for cell encapsulation and is well tolerated by various tissues. A wide spectrum of cells and tissues has been encapsulated and implanted, both in animals and humans, indicating the general applicability of this approach for both research and medical purposes, including CNS malignancies. Gliomas most frequently recur at the resection site. To provide local and sustained drug delivery, the bioreactors can be implanted in the brain parenchyma or in the ventricular system. The development of comprehensive analyses of geno- and phenotypic profiles of a tumor (genomics and proteomics) may provide new and important guidelines for choosing the optimal combination of bioreactors and recombinant proteins for therapeutic use.
Insights
Cell encapsulation offers a promising nonviral method for delivering therapeutic proteins to tumors, overcoming limitations of gene therapy. This technology enables localized, sustained treatment, particularly for challenging conditions like brain tumors.
Area of Science:
- Biotechnology
- Oncology
- Biomaterials Science
Background:
- Gene therapy via viral vectors has shown limited clinical success.
- Cell encapsulation provides a nonviral alternative for delivering therapeutic agents to tumors.
- This approach utilizes genetically engineered cells within protective capsules for localized treatment.
Purpose of the Study:
- To explore cell encapsulation as a viable strategy for localized tumor treatment.
- To highlight the potential of encapsulated cells as "bioreactors" for sustained therapeutic protein delivery.
- To discuss the application of this technology in treating central nervous system malignancies, such as gliomas.
Main Methods:
- Genetically engineered producer cells secreting therapeutic proteins are encapsulated in immunoisolating materials.
- Macro- and microencapsulation techniques are employed, with alginate being a common material.
- Encapsulated cells (bioreactors) are designed for transplantation and controlled release of recombinant proteins.
Main Results:
- Cell encapsulation technology has advanced significantly, with successful implantation in animal and human studies.
- Alginate encapsulation is well-tolerated and suitable for various tissues, including the brain.
- Bioreactors can be implanted in the brain for local, sustained drug delivery to target tumor recurrence sites.
Conclusions:
- Cell encapsulation is a versatile, nonviral platform for localized cancer therapy, especially for CNS tumors.
- Integration with tumor genomics and proteomics can optimize bioreactor design and therapeutic protein selection.
- This approach holds significant potential for improving treatment outcomes in oncology.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy